Tevogen Bio Holdings Inc.

Equities

TVGN

US88165K1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.8075 ^USD	+4.33%		-1.52%	-92.74%

May. 13	Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	MT
May. 13	Top Premarket Gainers	MT

Tevogen Bio Holdings Inc. announced that it expects to receive $2 million in funding

February 13, 2024

Tevogen Bio Holdings Inc. announced that it has entered into a share purchase agreement to issue 500 shares of Series A Preferred Stock of the company for an aggregate purchase price of $2,000,000 on February 14, 2024.

Latest news about Tevogen Bio Holdings Inc.

Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	May. 13	MT
Top Premarket Gainers	May. 13	MT
Tevogen Bio Holdings Inc. announced that it expects to receive $50 million in funding	May. 09	CI
Sector Update: Health Care Stocks Higher in Afternoon Trading	Apr. 26	MT
Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination	Apr. 26	MT
Top Premarket Gainers	Apr. 26	MT
Top Premarket Gainers	Apr. 04	MT
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development	Apr. 03	CI
Tevogen Bio Holdings Inc. amended terms of the transaction	Mar. 26	CI
Tevogen Bio Holdings Announces TVGN 489, its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant	Mar. 20	CI
Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment	Feb. 21	CI
Tevogen Bio Holdings Inc.(NasdaqGM:TVGN) added to NASDAQ Composite Index	Feb. 14	CI
Tevogen Bio Holdings Inc. announced that it expects to receive $2 million in funding	Feb. 13	CI
Tevogen Bio Holdings Inc. announced that it expects to receive $8 million in funding	Feb. 13	CI

Chart Tevogen Bio Holdings Inc.

Duration

Period

More charts

Company Profile

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TEVOGEN BIO HOLDINGS INC.	-92.74%	133M
MODERNA, INC.	+43.34%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research